REDMOND, Wash., Feb 23, 2026 — Today at the ISSAD meeting in Nairobi, Kenya, Prof. Shabir Madhi from the Wits Vaccines & Infectious Diseases Analytics (VIDA) Research Unit, Johannesburg, South Africa, will present interim results from a clinical study of Inventprise’s hexavalent Group B Streptococcus (GBS) vaccine candidate.

The first-in-human, Phase 1/2, randomized, placebo-controlled, observer-blinded study enrolled 600 healthy, non-pregnant women of childbearing age between November 12, 2024 and August 26, 2025 in New York, USA and Johannesburg, South Africa. Participants received a single dose of 2.5 µg, 7.5 µg, or 20 µg of IVT-GBS-06 (capsular polysaccharides representing serotypes Ia, Ib, II, III, V, and VII) or placebo on Day 1.

All vaccine dose levels were well tolerated, with no related serious adverse events reported. At Day 29, all formulations were immunogenic, with clear post-vaccination geometric mean concentration fold-rises relative to baseline observed across the 2.5 µg, 7.5 µg, and 20 µg dose groups for all six serotypes.

“We are pleased to report that in this Phase 1/2 trial, our vaccine candidate demonstrated a favorable safety and tolerability profile, along with robust immunogenicity across all dose levels,” said Dr. Subhash Kapre, Founder and Chairman of the Inventprise Board. “We are grateful to all study participants, investigators, and our partners at PATH and the Gates Foundation. We believe these findings represent an important step forward in the development of a much-needed maternal GBS vaccine.”